The role of intestinal microbiota and permeability in inflammation and in the pathogenesis of morbid obesity
Completed
- Conditions
- obesity1001842410019654
- Registration Number
- NL-OMON32675
- Lead Sponsor
- Academisch Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
Research population:
* BMI >35 kg/m2
* age 18-60 years;Healthy Controls:
* BMI 20-25
* age 18-60 years
Exclusion Criteria
* Age <18 or >60 years
* Diabetes Mellitus type I
* Inflammatory diseases such as auto-immune diseases (due to a higher inflammatory profile)
* Degenerative disase
* Alcohol or drug abuse
* use of corticosteroids and / or prednisolone (confounding effect on inflammatory status)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* BMI, hip/waist ratio<br /><br>* Intestinal permeability: excretion of orally administerd sugars in urine<br /><br>* Intestinale damage: plasma markers (IFABP, ILBP and LFABP)<br /><br>* Plasma inflammation markers (CRP, IL-6, TNF-*, MPO, PAI-1, adiponectin,<br /><br>leptin, endotoxin, Endocab)<br /><br>* Insulin resistence (glucose, insulin, HOMA-IR, HbA1c, lipids)</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>